Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Continues To Speed PD-1/L1 Drugs To Market

Executive Summary

The four-month review of Merck’s Keytruda for first-line lung cancer is a reminder of how quickly the agency has acted on the immune checkpoint inhibitors.


Related Content

Keeping Track: Immuno-Oncologics And Abuse-Deterrent Opioids Take Center Stage (Again); Jardiance CV Claim Approved
Pfizer’s Avelumab Poised For Speedy Review By FDA
Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola
How To Save A Drug: Iressa’s Return Relied On Consistency Across Totality Of Evidence
It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
FDA ‘Expedited Review’ Would Shave Off Additional Month For Some ‘Breakthrough’ Products
Will The New Math Of Oncology Drug Review Times Carry Over Into PDUFA V?


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst